NASDAQ:MIST Milestone Pharmaceuticals Q1 2025 Earnings Report $1.69 +0.00 (+0.12%) As of 10:41 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Milestone Pharmaceuticals EPS ResultsActual EPS-$0.31Consensus EPS -$0.19Beat/MissMissed by -$0.12One Year Ago EPSN/AMilestone Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMilestone Pharmaceuticals Announcement DetailsQuarterQ1 2025Date5/14/2025TimeBefore Market OpensConference Call DateWednesday, May 14, 2025Conference Call Time7:00AM ETUpcoming EarningsMilestone Pharmaceuticals' Q2 2025 earnings is scheduled for Thursday, August 14, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress ReleaseQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress ReleaseQuarterly report(10-Q) Milestone Pharmaceuticals Earnings HeadlinesMilestone Pharmaceuticals to Present at the Jefferies Global Healthcare ConferenceMay 28, 2025 | globenewswire.comMilestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives $17.00 Average Target Price from AnalystsMay 25, 2025 | americanbankingnews.comWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington. June 4, 2025 | Altimetry (Ad)Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate UpdateMay 15, 2025 | finanznachrichten.deMilestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate UpdateMay 14, 2025 | globenewswire.comMilestone Pharmaceuticals: A Golden Opportunity To Buy On Etripamil's CRL In PSVTApril 9, 2025 | seekingalpha.comSee More Milestone Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Milestone Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Milestone Pharmaceuticals and other key companies, straight to your email. Email Address About Milestone PharmaceuticalsMilestone Pharmaceuticals (NASDAQ:MIST), a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.View Milestone Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Ollie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record HighsUlta’s Beautiful Q1 Earnings Report Points to More Gains Aheade.l.f. Beauty Sees Record Surge After Earnings, Rhode DealCrowdStrike Stock Slips: Analyst Downgrades Before Earnings Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsAdvance Auto Parts: Did Earnings Defuse Tariff Concerns? Upcoming Earnings Broadcom (6/5/2025)Oracle (6/10/2025)Adobe (6/12/2025)Accenture (6/20/2025)FedEx (6/24/2025)Micron Technology (6/25/2025)Paychex (6/25/2025)NIKE (6/26/2025)PepsiCo (7/10/2025)Bank of America (7/14/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
